Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening

Lung cancer mortality rates, particularly non-small cell lung cancer (NSCLC), continue to present a significant global health challenge, and the adoption of lung cancer screening remains limited, often influenced by inequities in access to healthcare. Despite clinical evidence demonstrating the effi...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 13; no. 16; p. 4911
Main Authors Cotton, Lindsey B, Bach, Peter B, Cisar, Chris, Schonewolf, Caitlin A, Tennefoss, Demetria, Vachani, Anil, Carter-Bawa, Lisa, Zaidi, Ali H
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.08.2024
MDPI
Subjects
Biomarkers
Biopsy
blood-based testing
Cancer
Care and treatment
Clinical trials
Colon
Diagnosis
DNA methylation
Feasibility studies
low-dose computed tomography
Lung cancer
lung cancer screening
Medical screening
Mortality
NSCLC
Primary care
Review
screening adherence
Stigma
Tomography
USPSTF
United States
United States > US
DELFI
USPSTF
screening adherence
blood-based testing
lung cancer screening
NSCLC
fragmentomics
low-dose computed tomography
cell-free DNA
liquid biopsy
Online AccessGet full text

Cover

More Information
Summary:Lung cancer mortality rates, particularly non-small cell lung cancer (NSCLC), continue to present a significant global health challenge, and the adoption of lung cancer screening remains limited, often influenced by inequities in access to healthcare. Despite clinical evidence demonstrating the efficacy of annual screening with low-dose computed tomography (LDCT) and recommendations from medical organizations including the U.S. Preventive Services Task Force (USPSTF), the national lung cancer screening uptake remains around 5% among eligible individuals. Advancements in the clinical management of NSCLC have recently become more personalized with the implementation of blood-based biomarker testing. Extensive research into tumor-derived cell-free DNA (cfDNA) through fragmentation offers a novel method for improving early lung cancer detection. This review assesses the screening landscape, explores obstacles to lung cancer screening, and discusses how a plasma whole genome fragmentome test (pWGFrag-Lung) can improve lung cancer screening participation and adherence.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm13164911